Autologous CD34-positive cells (CD34+ cells) (CD34+ cells)

Autologous CD34-positive (CD34+) cells are a population of hematopoietic stem and progenitor cells utilized as a regenerative therapy for ischemic cardiovascular and peripheral vascular diseases. Unlike traditional pharmacological agents that bind to a single molecular target, these cells function as a multi-component therapeutic system that promotes vascular regeneration through paracrine signaling and direct cellular contribution to neoangiogenesis (Mackie and Losordo, 2011). Upon delivery to ischemic tissue, CD34+ cells secrete a potent cocktail of angiogenic growth factors, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), which stimulate the repair and expansion of the microvascular network (Losordo et al., 2007). This mechanism addresses the underlying pathology of patients with refractory angina or chronic limb-threatening ischemia by restoring blood flow to oxygen-deprived tissues (Henry et al., 2018). The therapeutic effect is mediated by the cells' innate ability to home to sites of injury and orchestrate a complex regenerative response, making them a unique class of 'living' therapeutics in regenerative medicine.

Other names

CD34+ hematopoietic stem and progenitor cellsAutologous CD34+ cellsHSPCsEndothelial progenitor cells

Autologous CD34+ cells promote revascularization of ischemic tissue through the secretion of angiogenic factors (paracrine effect) and potential differentiation into endothelial progenitor cells, leading to improved microvascular density and tissue perfusion (Mackie and Losordo, 2011).